NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP
InfuSystem Holdings, Inc. INFU
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$143.4M
▲ 6.4% vs FY2024
EPS · FY25
$0.31
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
11.5%
Net margin · FY25
4.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 143.4M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
5 cents of every revenue dollar became profit this year.
Per share
USD 0.31
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
11.5%
Return on equity, FY2025
ROE
Operating margin8.3%
Net margin4.6%
Return on assets6.5%
Each USD of equity produced 12 cents of profit this year.
Returned to shareholders
USD 9.9M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 9.9M
Share of profit148.9%
Consecutive raises—
USD 9.9M in buybacks — 149% of the year's profit, so the payout drew on cash built up earlier.
Growth
+8.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+9.3%
+8.1%
+7.4%
+7.7%
Net income
+616.7%
−17.5%
+9.1%
EPS, diluted
−17.3%
+10.0%
Returned to shareholders
+21.8%
+49.3%
+39.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years−0.4%
Change, 10 years−10.3%
The share count shrank 0% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 100.6M
total assets, end of FY2025
Total assetsUSD 100.6M
EquityUSD 57.3M
CashUSD 3.2M
Gross debtUSD 19.6M
Net debtUSD 16.4M
Current ratio1.80×
Net debt stands at 29% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
Operating income $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.1
−0.0
0.0
EBITDA $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.1
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
Net income $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
EPS, diluted $
0.31
0.11
0.04
0.00
0.06
0.80
0.07
−0.05
−0.91
−0.01
0.12
0.15
0.08
−0.07
−2.16
−0.09
0.04
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
11.5
4.3
1.7
0.0
3.2
54.9
6.4
−4.3
−50.7
−0.4
5.8
7.5
4.0
−3.7
−72.5
−2.2
1.0
Shares out B
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
56 of 65
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 8 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed